Rare, near-life-sized statues discovered in Pompeii tomb
Sign up for CNN's Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more.
Two very rare, almost-life-sized statues have been discovered during the excavation of a massive tomb in Pompeii.
Archaeologists say the marble funerary statues of a toga-clad man and a woman shed new light on the power held by priestesses in the ancient city, which was destroyed when Mount Vesuvius erupted in 79 AD.
Unearthed during ongoing excavations of the tomb just outside the Porto Sarno entrance gates of the dead city, the statue of the woman is slightly taller than that of the man by her side.
She is wearing lavish jewelry including earrings, bracelets and rings, as well as a necklace with a crescent moon pendant like those worn by priestesses of the cult of Ceres – a goddess of fertility, agriculture and motherly relationships – the Pompeii archaeological park said in a statement announcing the discovery.
The 'lunula,' or crescent moon pendant, was worn by priestesses to ward off evil forces from birth to marriage. 'The symbol of the crescent moon also had an atavistic and primordial meaning, linked to the fertility of the earth, abundance and rebirth, and influenced by the lunar cycles,' according to the research paper on the discovery, published online.
The woman's tunic is covered with a cape and she is holding what appears to be a papyrus roll and laurel leaves – often used for purifying and blessing religious spaces by dispersing the smoke from ceremonial incense throughout the area.
The woman's adornments suggest she was more important than the man, according to Gabriel Zuchtriegel, director of the Pompeii archaeological park. This, he said, could mean they were not married but that the man may have been either a priest or the woman's son.
The city of Pompeii was buried under ash and volcanic glass when Vesuvius erupted, and archaeologists have been unearthing it since the 1700s, in a large, ongoing excavation.
The current dig, called the Investigating the Archeology of Death in Pompeii Research Project, began in July 2024 and is led by Spanish archaeologist Llorenç Alapont, in conjunction with the University of Valencia and the archeological park.
The area was discovered in 1998 during the construction of a train line from Naples. So far, more than 50 cremation burial sites have been identified.
'This campaign is a precious opportunity to expand research and enhancement activities in the area outside the walls of Pompeii,' Zuchtriegel said in a press statement sent to CNN.
Previous discoveries in the same area include mummified remains. They were found in 2021 at the necropolis of Porta Sarno, in a tomb bearing a commemorative inscription dedicated to Marcus Venerius Secundio, a public slave and custodian of the Temple of Venus.
'Thanks to the collaboration with the University of Valencia, to which we also owe the discovery a few years ago of the Tomb of Marco Venerio Secundio in the same area, it was possible to work on a multidisciplinary project that saw the involvement of different professionals in the various phases, including archaeologists, architects, restorers, and anthropologists,' Zuchtriegel said.
The sculptures belong to what the archeologists working on the dig classify as a large class of funerary reliefs made between the first century BC and the first century AD, Alapont said.
These examples appear to date from the Late Republic era, between 133 and 31 BC, according to the research paper.
'Nevertheless, these types of sculptures are very rare in southern Italy. It is even more unusual to find reliefs of priestesses holding their religious objects,' Alapont said in the statement. 'It is clear that there were priestesses of Ceres in Pompeii, but this statue provides new evidence of the importance of the cult in the city.
'In addition, the cult of Ceres has been linked to the popular classes. However, the ostentation of the female relief may suggest that the status of priestess was still reserved for women belonging to a relatively high social standing.'
The statues have been moved to the Palestra Grande, the largest open space in Pompeii, to be restored and will be featured in the exhibition 'Being a Woman in Ancient Pompeii,' which opens in the archaeological park on April 16.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
These 12 Fruits and Vegetables Have the Most Pesticides — Does Your Family Eat Them?
The advocacy and watchdog organization Environmental Working Group has released its annual 'Dirty Dozen' list of the produce items with the highest levels of pesticides Topping the list is spinach, which EWG says includes a pesticide that's banned in Europe Potatoes were also found to have a pesticide that's banned in EuropeAn annual list of of produce items with high levels of pesticides says leafy greens and fruit are loaded with toxins — including some that are banned in Europe. Dubbed the 'Dirty Dozen,' twelve popular produce items were found to contain high levels of pesticides and fungicides, according to a new report from nonprofit activist and watchdog group, Environmental Working Group. Topping the list was spinach; EWG's report says they found an average of seven pesticides on the leafy greens sampled, and 76% of the samples contained permethrin, which was banned in Europe in 2002. As the U.S. Environmental Protection Agency says, it's 'classified permethrin as 'Likely to be Carcinogenic to Humans' by the oral route' and is restricted to use on crops and farms only. Rounding out the list were strawberries, kale (and mustard greens and collards), grapes, peaches, cherries, nectarines, pears, apples, blackberries, blueberries and potatoes. The spuds also include a pesticide that's banned in Europe, chlorpropham, which the EPA says is used to 'inhibit sprouting in stored potatoes.' The research was conducted using data from the 53,692 samples of 47 fruits and vegetables from the USDA, and found that 75% of the non-organic samples contained pesticides. Blackberries made the list for the first time, with EWG saying one sample had 14 different pesticide residues. The advocacy group's vice president of science, Alexis Temkin, told CNN, 'The guide is there to help consumers eat a lot of fruits and vegetables while trying to reduce pesticide exposure … One of the things that a lot of peer-reviewed studies have shown over and over again [is] that when people switch to an organic diet from a conventional diet, you can really see measurable levels in the reduction of pesticide levels in the urine.' The group also releases a list of the 'Clean Fifteen' — aka, the produce items with the lowest amount of pesticides. These include pineapples, sweet corn (both fresh and frozen), avocados, papaya, onions, frozen sweet peas, asparagus, cabbage, watermelon, cauliflower, bananas, mangos, carrots, mushrooms and kiwis. Most of these produce items do not have an edible skin, which is a common thread with the fruit and vegetables that the group says have high pesticide levels. The Alliance for Food and Farming's executive director, Teresa Thorne, told CNN, 'consumers should be reassured by decades of toxicology studies, government data and nutrition research which underscores the importance of a diet rich in fruits and vegetables on health and the safety of both organic and conventionally grown produce.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Read the original article on People
Yahoo
5 hours ago
- Yahoo
These 12 Fruits and Vegetables Have the Most Pesticides — Does Your Family Eat Them?
The advocacy and watchdog organization Environmental Working Group has released its annual 'Dirty Dozen' list of the produce items with the highest levels of pesticides Topping the list is spinach, which EWG says includes a pesticide that's banned in Europe Potatoes were also found to have a pesticide that's banned in EuropeAn annual list of of produce items with high levels of pesticides says leafy greens and fruit are loaded with toxins — including some that are banned in Europe. Dubbed the 'Dirty Dozen,' twelve popular produce items were found to contain high levels of pesticides and fungicides, according to a new report from nonprofit activist and watchdog group, Environmental Working Group. Topping the list was spinach; EWG's report says they found an average of seven pesticides on the leafy greens sampled, and 76% of the samples contained permethrin, which was banned in Europe in 2002. As the U.S. Environmental Protection Agency says, it's 'classified permethrin as 'Likely to be Carcinogenic to Humans' by the oral route' and is restricted to use on crops and farms only. Rounding out the list were strawberries, kale (and mustard greens and collards), grapes, peaches, cherries, nectarines, pears, apples, blackberries, blueberries and potatoes. The spuds also include a pesticide that's banned in Europe, chlorpropham, which the EPA says is used to 'inhibit sprouting in stored potatoes.' The research was conducted using data from the 53,692 samples of 47 fruits and vegetables from the USDA, and found that 75% of the non-organic samples contained pesticides. Blackberries made the list for the first time, with EWG saying one sample had 14 different pesticide residues. The advocacy group's vice president of science, Alexis Temkin, told CNN, 'The guide is there to help consumers eat a lot of fruits and vegetables while trying to reduce pesticide exposure … One of the things that a lot of peer-reviewed studies have shown over and over again [is] that when people switch to an organic diet from a conventional diet, you can really see measurable levels in the reduction of pesticide levels in the urine.' The group also releases a list of the 'Clean Fifteen' — aka, the produce items with the lowest amount of pesticides. These include pineapples, sweet corn (both fresh and frozen), avocados, papaya, onions, frozen sweet peas, asparagus, cabbage, watermelon, cauliflower, bananas, mangos, carrots, mushrooms and kiwis. Most of these produce items do not have an edible skin, which is a common thread with the fruit and vegetables that the group says have high pesticide levels. The Alliance for Food and Farming's executive director, Teresa Thorne, told CNN, 'consumers should be reassured by decades of toxicology studies, government data and nutrition research which underscores the importance of a diet rich in fruits and vegetables on health and the safety of both organic and conventionally grown produce.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Read the original article on People
Yahoo
11 hours ago
- Yahoo
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
-Data highlights potential of ZL-1503 as a promising treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases -Favorable preclinical safety profile, prolonged half-life and durable suppression of both inflammatory and pruritogenic pathways support advancement of ZL-1503 to IND-enabling studies -Zai Lab plans to file an IND for ZL-1503 for moderate-to-severe atopic dermatitis by the end of 2025 SHANGHAI & CAMBRIDGE, Mass., June 13, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from its preclinical study of ZL-1503, the Company's promising IL-13/IL-31R bispecific antibody, demonstrating its ability to simultaneously suppress the inflammatory and pruritogenic (itch-causing) pathways in atopic dermatitis (AD). The findings, featured during a poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, Scotland, highlight the potential of ZL-1503 as a novel treatment option for moderate-to-severe AD. Medications that inhibit IL-4/IL-13 signaling have markedly improved the therapeutic landscape for AD. Certain AD symptoms are mediated by IL-31; however, they are only partially alleviated by IL-4/IL-13 inhibition. As a result, many patients experience slow and modest clinical responses to currently available medications. ZL-1503 was evaluated in a pilot preclinical study in non-human primates to assess its long-term effects on IL-31-mediated scratching and IL-13-induced signaling (pSTAT6). Key study results presented at the EAACI Congress 2025 include: An intravenous single dose of ZL-1503 (10 mg/kg, iv) completely inhibited IL-13-mediated pSTAT6 and IL-31-induced scratching for at least 76 days in all preclinical subjects. Two out of three subjects exhibited prolonged IL-13-mediated pSTAT6 inhibition for over 118 days, and one out of three subjects sustained IL-31-induced scratching inhibition for over 133 days. Pharmacokinetic (PK) analysis of serum samples collected during the study revealed that ZL-1503 exhibited slow clearance, correlating closely pharmacodynamic (PD) responses, demonstrating strong PK/PD relationships in blocking IL-13 and IL-31 pathways in the preclinical model. ZL-1503 was well tolerated following weekly IV dosing up to 150 mg/kg. Additionally, in vitro studies showed that binding to one target did not affect ZL-1503's blocking effects on the other target. Details regarding the ZL-1503 poster presentation at EAACI Congress 2025 are as follows: Title: ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates Presenter: Linda Liu, Ph.D., Senior Vice President, Biologics Discovery, Zai LabSession Title: Thematic Poster Session 18 (TPS18), Biologicals 01Date/Time: Friday, June 13, 2025, from 12:00 - 13:00 BSTAbstract Number and Location: n°000625 & Poster Prefix D1.365, Poster Zone About Zai Lab Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health worldwide. For additional information about Zai Lab, please visit or follow us at Zai Lab Forward-Looking Statements This press release contains forward-looking statements relating to our future expectations, plans, and prospects, including, without limitation, statements regarding product candidates in our pipeline including ZL-1503 and related preclinical studies; the potential benefits of ZL-1503; and the potential treatment of atopic dermatitis and other diseases involving the IL-13 and IL-31 pathways. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and the SEC's website at View source version on Contacts Investor Relations: Christine Chiou / Lina Zhang+1 (917) 886-6929 / +86 136 8257 / Media: Shaun Maccoun / Xiaoyu Chen+1 (857) 270-8854 / +86 185 0015 / Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data